Brief: Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting With FDA For Tonmya™ For The Management Of Fibromyalgia
08/07/2024 13:15
July 8 (Reuters) - Tonix Pharmaceuticals Holding Corp
TNXP.O :
* TONIX PHARMACEUTICALS REPORTS FINAL POSITIVE PRE-NDA
MEETING
WITH FDA FOR TONMYA™ FOR THE MANAGEMENT OF FIBROMYALGIA
* TONIX PHARMACEUTICALS HOLDING CORP - NDA SUBMISSION TARGET
CONFIRMED FOR SECOND HALF 2024, WITH POTENTIAL FOR FDA APPROVAL
IN SECOND HALF 2025
Source text for Eikon: ID:nGNX1bJj6D
Further company coverage: TNXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview